Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

dc.contributor.authorPeres, Fernanda Fiel [UNIFESP]
dc.contributor.authorLima, Alvaro C.
dc.contributor.authorHallak, Jaime E. C.
dc.contributor.authorCrippa, José Alexandre de Souza [UNIFESP]
dc.contributor.authorSilva, Regina Helena da [UNIFESP]
dc.contributor.authorAbilio, Vanessa Costhek [UNIFESP]
dc.date.accessioned2018-07-26T12:18:48Z
dc.date.available2018-07-26T12:18:48Z
dc.date.issued2018
dc.description.abstractMovement disorders such as Parkinson's disease and dyskinesia are highly debilitating conditions linked to oxidative stress and neurodegeneration. When available, the pharmacological therapies for these disorders are still mainly symptomatic, do not benefit all patients and induce severe side effects. Cannabidiol is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. Although the studies that investigate the effects of this compound on movement disorders are surprisingly few, cannabidiol emerges as a promising compound to treat and/or prevent them. Here, we review these clinical and pre-clinical studies and draw attention to the potential of cannabidiol in this field.en
dc.description.affiliationUniv Fed Sao Paulo, Dept Pharmacol, Lab Behav Neurosci, Sao Paulo, Brazil
dc.description.affiliationNatl Inst Translat Med INCT TM, CNPq, FAPESP, CAPES, Ribeirao Preto, Brazil
dc.description.affiliationUniv Sao Paulo, Dept Neurosci & Behav, Ribeirao Preto, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Pharmacol, Lab Behav Neurosci, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil)
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
dc.description.sponsorshipFundacao de Apoio ao Ensino, Pesquisa e Assistencia do Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo (FAEPA, Brazil)
dc.description.sponsorshipCenter for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of Sao Paulo, Sao Paulo, Brazil (NAPNA)
dc.description.sponsorshipNational Institute for Translational Medicine (INCT-TM)
dc.description.sponsorshipNational Institute for Translational Medicine (CNPq/FAPESP, Brazil)
dc.description.sponsorshipUniversity Global Partnership Network (UGPN)-Global priorities in cannabinoid research excellence
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.3389/fphar.2018.00482
dc.identifier.citationFrontiers In Pharmacology. Lausanne, v. 9, p. -, 2018.
dc.identifier.doi10.3389/fphar.2018.00482
dc.identifier.fileWOS000431876000001.pdf
dc.identifier.issn1663-9812
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/46042
dc.identifier.wosWOS:000431876000001
dc.language.isoeng
dc.publisherFrontiers Media Sa
dc.rightsAcesso aberto
dc.subjectcannabidiolen
dc.subjectmovement disordersen
dc.subjectParkinson's diseaseen
dc.subjectHuntington's diseaseen
dc.subjectdystonic disordersen
dc.subjectcannabinoidsen
dc.titleCannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?en
dc.typeRevisão
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
WOS000431876000001.pdf
Tamanho:
811.41 KB
Formato:
Adobe Portable Document Format
Descrição:
Coleções